LDB1 and carcinoma: Carcinoma cells in the lymph nodes significantly increased the immunoreactivity of LMO4 (37.67±22.60) and LDB1 (38.07±23.84) compared to the corresponding primary sites (LMO4; 13.46±18.29, LDB1; 17.63±14.99) (Figure 5B).